Shifang Sun, Shungen Xiao, Zhen Jiang, Junfeng Xiao, Qi He, Mei Wang, Yanfen Fan
{"title":"对比增强 CT 的放射线组学分析可预测 Glypican 3 阳性肝细胞癌","authors":"Shifang Sun, Shungen Xiao, Zhen Jiang, Junfeng Xiao, Qi He, Mei Wang, Yanfen Fan","doi":"10.2174/0115734056277475240215115629","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Glypican 3 (GPC3)-positive expression in Hepatocellular Carcinoma (HCC) is associated with a worse prognosis. Moreover, GPC3 has emerged as an immunotherapeutic target in advanced unresectable HCC systemic therapy. It is significant to diagnose GPC3-positive HCCs before therapy. Regarding imaging diagnosis of HCC, dynamic contrast-enhanced CT is more common than MRI in many regions.</p><p><strong>Objective: </strong>The aim of this study was to construct and validate a radiomics model based on contrast-enhanced CT to predict the GPC3 expression in hepatocellular carcinoma.</p><p><strong>Methods: </strong>This retrospective study included 141 (training cohort: n = 100; validation cohort: n = 41) pathologically confirmed HCC patients. Radiomics features were extracted from the Artery Phase (AP) images of contrast-enhanced CT. Logistic regression with the Least Absolute Shrinkage and Selection Operator (LASSO) regularization was used to select features to construct radiomics score (Rad-score). A final combined model, including the Rad-score of the selected features and clinical risk factors, was established. Receiver Operating Characteristic (ROC) curve analysis, Delong test, and Decision Curve Analysis (DCA) were used to assess the predictive performance of the clinical and radiomics models.</p><p><strong>Results: </strong>5 features were selected to construct the AP radiomics model of contrast-enhanced CT. The radiomics model of AP from contrast-enhanced CT was superior to the clinical model of AFP in training cohorts (P < 0.001), but not superior to the clinical model in validation cohorts (P = 0.151). The combined model (AUC = 0.867 vs. 0.895), including AP Rad-score and serum Alpha-Fetoprotein (AFP) levels, improved the predictive performance more than the AFP model (AUC = 0.651 vs. 0.718) in the training and validation cohorts. The combined model, with a higher decision curve indicating more net benefit, exhibited a better predictive performance than the AP radiomics model. DCA revealed that at a range threshold probability approximately above 60%, the combined model added more net benefit compared to the AP radiomics model of contrastenhanced CT.</p><p><strong>Conclusion: </strong>A combined model including AP Rad-score and serum AFP levels based on contrast-enhanced CT could preoperatively predict GPC3-positive expression in HCC.</p>","PeriodicalId":54215,"journal":{"name":"Current Medical Imaging Reviews","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma.\",\"authors\":\"Shifang Sun, Shungen Xiao, Zhen Jiang, Junfeng Xiao, Qi He, Mei Wang, Yanfen Fan\",\"doi\":\"10.2174/0115734056277475240215115629\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The Glypican 3 (GPC3)-positive expression in Hepatocellular Carcinoma (HCC) is associated with a worse prognosis. Moreover, GPC3 has emerged as an immunotherapeutic target in advanced unresectable HCC systemic therapy. It is significant to diagnose GPC3-positive HCCs before therapy. Regarding imaging diagnosis of HCC, dynamic contrast-enhanced CT is more common than MRI in many regions.</p><p><strong>Objective: </strong>The aim of this study was to construct and validate a radiomics model based on contrast-enhanced CT to predict the GPC3 expression in hepatocellular carcinoma.</p><p><strong>Methods: </strong>This retrospective study included 141 (training cohort: n = 100; validation cohort: n = 41) pathologically confirmed HCC patients. Radiomics features were extracted from the Artery Phase (AP) images of contrast-enhanced CT. Logistic regression with the Least Absolute Shrinkage and Selection Operator (LASSO) regularization was used to select features to construct radiomics score (Rad-score). A final combined model, including the Rad-score of the selected features and clinical risk factors, was established. Receiver Operating Characteristic (ROC) curve analysis, Delong test, and Decision Curve Analysis (DCA) were used to assess the predictive performance of the clinical and radiomics models.</p><p><strong>Results: </strong>5 features were selected to construct the AP radiomics model of contrast-enhanced CT. The radiomics model of AP from contrast-enhanced CT was superior to the clinical model of AFP in training cohorts (P < 0.001), but not superior to the clinical model in validation cohorts (P = 0.151). The combined model (AUC = 0.867 vs. 0.895), including AP Rad-score and serum Alpha-Fetoprotein (AFP) levels, improved the predictive performance more than the AFP model (AUC = 0.651 vs. 0.718) in the training and validation cohorts. The combined model, with a higher decision curve indicating more net benefit, exhibited a better predictive performance than the AP radiomics model. DCA revealed that at a range threshold probability approximately above 60%, the combined model added more net benefit compared to the AP radiomics model of contrastenhanced CT.</p><p><strong>Conclusion: </strong>A combined model including AP Rad-score and serum AFP levels based on contrast-enhanced CT could preoperatively predict GPC3-positive expression in HCC.</p>\",\"PeriodicalId\":54215,\"journal\":{\"name\":\"Current Medical Imaging Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Medical Imaging Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115734056277475240215115629\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Imaging Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734056277475240215115629","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
背景:肝细胞癌(HCC)中 Glypican 3 (GPC3) 阳性表达与预后较差有关。此外,GPC3 已成为晚期不可切除 HCC 系统治疗的免疫治疗靶点。在治疗前诊断 GPC3 阳性的 HCC 意义重大。关于 HCC 的影像诊断,在许多地区,动态对比增强 CT 比 MRI 更为常见:本研究旨在构建并验证基于对比增强 CT 的放射组学模型,以预测肝细胞癌中 GPC3 的表达:这项回顾性研究纳入了 141 例(训练队列:n = 100;验证队列:n = 41)病理确诊的 HCC 患者。从对比增强 CT 的动脉期(AP)图像中提取放射组学特征。使用带有最小绝对收缩和选择操作符(LASSO)正则化的逻辑回归来选择特征,构建放射组学评分(Rad-score)。最终建立了包括所选特征的 Rad-score 和临床风险因素的综合模型。采用接收者工作特征曲线(ROC)分析、Delong 检验和决策曲线分析(DCA)来评估临床和放射组学模型的预测性能:结果:选择了5个特征来构建对比增强CT的AP放射组学模型。对比增强 CT 的 AP 放射组学模型在训练队列中优于 AFP 临床模型(P < 0.001),但在验证队列中不优于临床模型(P = 0.151)。在训练队列和验证队列中,包括 AP Rad 评分和血清甲胎蛋白(AFP)水平的组合模型(AUC = 0.867 vs. 0.895)比 AFP 模型(AUC = 0.651 vs. 0.718)更能提高预测性能。与 AP 放射组学模型相比,综合模型的决策曲线更高,表明净获益更多,因此具有更好的预测性能。DCA显示,在范围阈值概率约高于60%时,与造影剂增强CT的AP放射组学模型相比,联合模型增加了更多的净收益:结论:基于造影剂增强 CT 的 AP Rad 评分和血清 AFP 水平的组合模型可以在术前预测 HCC 中 GPC3 阳性表达的情况。
Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma.
Background: The Glypican 3 (GPC3)-positive expression in Hepatocellular Carcinoma (HCC) is associated with a worse prognosis. Moreover, GPC3 has emerged as an immunotherapeutic target in advanced unresectable HCC systemic therapy. It is significant to diagnose GPC3-positive HCCs before therapy. Regarding imaging diagnosis of HCC, dynamic contrast-enhanced CT is more common than MRI in many regions.
Objective: The aim of this study was to construct and validate a radiomics model based on contrast-enhanced CT to predict the GPC3 expression in hepatocellular carcinoma.
Methods: This retrospective study included 141 (training cohort: n = 100; validation cohort: n = 41) pathologically confirmed HCC patients. Radiomics features were extracted from the Artery Phase (AP) images of contrast-enhanced CT. Logistic regression with the Least Absolute Shrinkage and Selection Operator (LASSO) regularization was used to select features to construct radiomics score (Rad-score). A final combined model, including the Rad-score of the selected features and clinical risk factors, was established. Receiver Operating Characteristic (ROC) curve analysis, Delong test, and Decision Curve Analysis (DCA) were used to assess the predictive performance of the clinical and radiomics models.
Results: 5 features were selected to construct the AP radiomics model of contrast-enhanced CT. The radiomics model of AP from contrast-enhanced CT was superior to the clinical model of AFP in training cohorts (P < 0.001), but not superior to the clinical model in validation cohorts (P = 0.151). The combined model (AUC = 0.867 vs. 0.895), including AP Rad-score and serum Alpha-Fetoprotein (AFP) levels, improved the predictive performance more than the AFP model (AUC = 0.651 vs. 0.718) in the training and validation cohorts. The combined model, with a higher decision curve indicating more net benefit, exhibited a better predictive performance than the AP radiomics model. DCA revealed that at a range threshold probability approximately above 60%, the combined model added more net benefit compared to the AP radiomics model of contrastenhanced CT.
Conclusion: A combined model including AP Rad-score and serum AFP levels based on contrast-enhanced CT could preoperatively predict GPC3-positive expression in HCC.
期刊介绍:
Current Medical Imaging Reviews publishes frontier review articles, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances on medical imaging dedicated to clinical research. All relevant areas are covered by the journal, including advances in the diagnosis, instrumentation and therapeutic applications related to all modern medical imaging techniques.
The journal is essential reading for all clinicians and researchers involved in medical imaging and diagnosis.